Fundación Huésped

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 773 citations · Full text

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

Frank van Leth, Praphan Phanuphak, Kiat Ruxrungtham et al. · The Lancet · 2004 · 683 citations

Treatment And Prevention, Medicine, First-line Antiretroviral Therapy +9

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 523 citations · Full text

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

José Valdez Madruga, Pedro Cahn, Beatriz Grinsztejn et al. · The Lancet · 2007 · 515 citations

Treatment-experienced Hiv-1-infected Patients, Treatment And Prevention, Human Retrovirus +11

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 507 citations · Full text

Treatment And Prevention, Week 48, Antiviral Drug Development +7